NATICK, Mass., Oct. 13 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced the global launch of its Journey™ Guidewire, an innovative 0.014″ guidewire designed for use in challenging, small vessel peripheral angioplasty procedures. The Journey Guidewire strengthens Boston Scientific’s broad portfolio of devices designed to address physician needs in treating arteries below the knee.
James Benenati, M.D., Medical Director of the Baptist Cardiac and Vascular Institute in Miami, and President of the Society of Interventional Radiology, has performed some of the initial procedures using the new Journey Guidewire, including a live case at the recent Transcatheter Cardiovascular Therapeutics scientific symposium.
“In my experience, the Journey Guidewire provides exceptional torque and flexibility, particularly in difficult cases involving small vessels or tortuous anatomy,” said Dr. Benenati. “This highly durable guidewire offers outstanding precision and tracking to help access the toughest peripheral lesions.”
Guidewires are thin, flexible wires used to facilitate the placement of balloon catheters or other therapeutic devices. The Journey Guidewire builds on Boston Scientific’s advanced guidewire technology used in coronary and neurovascular interventions. It features a micro-cut nitinol sleeve designed to provide efficient transmission of torque energy for more precise turn-by-turn response and control compared to conventional spring-coil guidewires. The nitinol distal core and hydrophilic coating are designed to enhance wire durability, tactile response and device delivery for improved overall performance.
“The Journey Guidewire reflects Boston Scientific’s commitment to providing physicians the most advanced solutions for peripheral interventions,” said Joe Fitzgerald, Senior Vice President and President of Boston Scientific’s Endovascular Unit. “Journey enhances our below-the-knee portfolio, which includes a number of leading products to treat this challenging anatomy.”
About Boston Scientific
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend” and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding new product launches and launch cadence, regulatory approvals, clinical trials, product performance and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.
SOURCE
